Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV Cipargamin in Healthy Subjects
NCT04321252Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cipargamin in malaria (7 cohorts), sponsored by Novartis. Primary endpoint: Number of Participants With On-Treatments Adverse Events, Serious Adverse Events, and Deaths. Started Jul 2020; status: completed.
02
Drugs
cipargamin
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04321252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04321252.